HLS Therapeutics Inc has seen a notable decline in its stock performance this week, raising concerns among investors.
This week, HLS Therapeutics Inc (HLS.TO) experienced a significant downturn, closing at C$3.70, down 4.95% on the day and 5.68% over the week. The stock has struggled to maintain momentum, reflecting broader concerns in the healthcare sector amid mixed financial results and changing market dynamics.
Investor takeaway: Investors should carefully consider the recent financial performance and operational developments of HLS Therapeutics, particularly in light of its declining stock price and the company's efforts to strengthen its balance sheet.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$141.37M
52W high
$5.61
52W low
$3.56
1W change
+10.12%
Beta
0.76
Analyst Price Targets
Based on analyst covering HLS · as of Oct 28, 2026
Wall Street analysts forecast HLS stock price to rise 62.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.41
+62.2% Upside
Previously C$7.38 on Oct 27, 2026
Current Price
C$4.57
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
43.6%
Annualized
90-Day Vol
39.2%
Annualized
Trend (90d)
+35.5%
Annualized drift
90d Mean
C$5.19
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.77 | C$4.10 – C$5.54 |
| 60 trading days | C$4.97 | C$4.02 – C$6.15 |
| 90 trading days | C$5.19 | C$4.00 – C$6.73 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
HLS Therapeutics Reports Declining Stock Performance Amid Mixed Financial Results
Despite reporting revenue growth in certain quarters, the overall market sentiment has led to a 24.74% decline in the stock year-to-date, highlighting investor caution.
Bull case
HLS Therapeutics is actively expanding its product offerings and has seen growth in net sales for key products, including Vascepa. This growth could signal potential for future revenue increases.
Bear case
The company's recent financial results show a negative profit margin and declining stock performance, raising concerns about its long-term viability and ability to generate consistent profits.
Recent Price Action
HLS Therapeutics Inc (HLS.TO) has seen a significant decline in its stock price, closing at C$3.70. This represents a 4.95% drop on the day and a 5.68% decrease over the week. Year-to-date, the stock has fallen by approximately 24.74%, indicating a challenging environment for the company.
Company News and Financial Results
Advertisement
While there were no major news releases this week, HLS Therapeutics recently reported its Q2 2026 financial results, showing a revenue of $13.5 million and cash from operations at $2.9 million. The company also repaid $1.1 million of its long-term debt, reflecting efforts to improve its financial position. Notably, previous quarters showed revenue growth, particularly with Vascepa net sales increasing by 15% in Q1 2026, marking the strongest growth since Q2 2025.
Technical Picture
The technical indicators for HLS Therapeutics suggest a bearish trend, with the stock trading below both its 50-day moving average of C$4.15 and its 200-day moving average of C$4.52, indicating downward momentum. The 52-week range for the stock is C$3.56 to C$5.76, with the current price at approximately 6% of this range. The stock has a beta of 0.86, suggesting lower volatility compared to the market. Trading volume has also been below average, with the latest volume at 34,900 shares compared to a 20-day average of 78,586 shares, indicating reduced investor interest.
Insider Activity
No recent insider activity has been reported for HLS Therapeutics, which may provide additional insight into the confidence of company executives in the current stock performance.
Price Action Summary
HLS Therapeutics Inc closed at C$3.70, reflecting a 1-day decline of 4.95%. The stock's ongoing performance will be closely monitored by investors as they assess the company's financial health and market conditions.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
